U.S. FDA approves Pfizer drug for menopause symptoms
(Reuters) - U.S. health regulators approved Pfizer Inc's menopause drug Duavee, which the company hopes will reduce hot flashes with fewer side effects than older hormone-replacement therapies.
The Food and Drug Administration said on Thursday it approved the drug to treat women with moderate to severe menopause symptoms and to prevent post-menopausal osteoporosis, a bone disease which can increase the risk of fractures.
The drug, which Pfizer is developing with Ligand Pharmaceuticals Inc, combines bazedoxifene - which belongs to a class of drugs known as selective estrogen receptor modulators, or SERMS - and conjugated estrogens, which are derived from the urine of pregnant horses and contained in Pfizer's menopause drug Premarin.
(Reporting by Toni Clarke in Washington; Editing by Gerald E. McCormick)
- Nurse defies Ebola quarantine with bike ride; negotiations fail |
- Suspect in Pennsylvania police ambush captured after seven-week manhunt |
- Global shares jump, yen slumps as BOJ cranks up stimulus |
- Japan's central bank shocks markets with more easing as inflation slows
- Special Report: Tsunami evacuees caught in $30 billion Japan money trap